CBLI - クリ―ブランド・バイオラブ （Cleveland BioLabs Inc.） クリ―ブランド・バイオラブCBLIのチャート
CBLIの企業情報
| symbol | CBLI |
|---|---|
| 会社名 | Cleveland BioLabs Inc （クリ―ブランド・バイオラブ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Commercial Physical_Biological Resarch |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 クリーブランド・バイオラブズ(Cleveland BioLabs Inc. )は臨床段階のバイオテクノロジー企業であり、腫瘍治療用医薬品の開発に取り組む。同社の主力薬品候補である「CBLB502」は、放射線対策として、一般的に動物ルール（Animal Rule）と呼ばれ、米国食品医薬品局（FDA）の動物有効性ルール（Animal Efficacy Rule）の下で、並びに抗がん剤と腫瘍支持療法としてFDAの従来の新薬承認経路下で、二重適応症のために開発されたものである。平成23年12月31日現在、同社の製品パイプラインにおける９つの薬品候補は同社自体およびその過半数所有子会社により直接的に開発されている。当該製品は「CBLB502」、「CBLB502」、「CBLB502」、「CBLB612」、「CBLC102」、「CBLC137、」「Revercom」、「Mobilan」、「Arkil」、「Antimycon」及び「Xenomycins」を含む。平成23年12月31日現在、同社はIncuron LLC (Incuron)の約75.8％の持分を所有し、Panacela Labs Inc. (Panacela)の約54.6％の持合株式を所有している。 クリ―ブランド・バイオラブは、米国の薬剤開発会社。医療ニ―ズが満たされていない病気に対処する医薬品の設計や開発に従事する。細胞死を制御するための薬理学的アプロ―チ、がん細胞を消滅させ、健康な細胞を保護することに焦点を当てる。 主要製品は、｢Entolimod｣と｢CBL0137｣がある。 |
| 本社所在地 | 73 High Street Buffalo NY 14203 USA |
| 代表者氏名 | Langdon L. Miller Langdon L. Miller |
| 代表者役職名 | President 社長 |
| 電話番号 | +1 716-849-6810 |
| 設立年月日 | 37773 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2006年 |
| 従業員数 | 19人 |
| url | www.cbiolabs.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cbli |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -5.29598 |
| 終値（lastsale） | 1.9799 |
| 時価総額（marketcap） | 22369383.3961 |
| 時価総額 | 時価総額（百万ドル） 22.25753 |
| 売上高 | 売上高（百万ドル） 1.78640 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 15.73004 |
| 当期純利益 | 当期純利益（百万ドル） -4.50562 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cleveland BioLabs Inc. revenues decreased 21% to $619K. Net loss decreased 71% to $2.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Change in value of warrant liability increase from $4.2M (expense) to $679K (income) Research and development decrease of 14% to $2.2M (expense). |
CBLIのテクニカル分析
CBLIのニュース
Cytocom Inc. Announces Completed Merger with Cleveland BioLabs 2021/07/28 12:30:00 PR Newswire
FORT COLLINS, Colo., July 28, 2021 /PRNewswire/ -- Cytocom Inc. ("Cytocom" or "Company"), a leading biopharmaceutical company creating next-generation therapies that focus on immune homeostasis, today announced the completion of its merger with Cleveland BioLabs, Inc. The all-stock
Earnings Report: Heres what to expect from Cleveland BioLabs (NASDAQ:CBLI) 2021/07/02 13:20:00 Stock Market Daily
Earnings results for Cleveland BioLabs , Analyst Opinion on Cleveland BioLabs , Earnings and Valuation of (NASDAQ:CBLI), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Earnings Report: Heres what to expect from Cleveland BioLabs (NASDAQ:CBLI) appeared first on .
CBLI liquidators lose ground with frivolous PwC suit 2021/06/18 03:54:12 National Business Review
CBLI liquidators lose ground with frivolous PwC suit reweti 18 Jun 21
Earnings Report: Heres what to expect from Cleveland BioLabs (NASDAQ:CBLI) 2021/07/02 13:20:00 Stock Market Daily
Earnings results for Cleveland BioLabs , Analyst Opinion on Cleveland BioLabs , Earnings and Valuation of (NASDAQ:CBLI), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Earnings Report: Heres what to expect from Cleveland BioLabs (NASDAQ:CBLI) appeared first on .
CBLI liquidators lose ground with frivolous PwC suit 2021/06/18 03:54:12 National Business Review
CBLI liquidators lose ground with frivolous PwC suit reweti 18 Jun 21
Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC 2021/06/17 22:37:00 Finanzen CH
FORT COLLINS, Colo. and BUFFALO, N.Y., June 17, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, announced that its
How Have the Numbers Shaped Up for Cleveland BioLabs (NASDAQ:CBLI) 2021/06/11 14:15:00 Stock Market Daily
Earnings results for Cleveland BioLabs , Analyst Opinion on Cleveland BioLabs , Earnings and Valuation of (NASDAQ:CBLI), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post How Have the Numbers Shaped Up for Cleveland BioLabs (NASDAQ:CBLI) appeared first on .
SHAREHOLDER ALERT: WeissLaw LLP Reminds TLRY, CBLI, AKER and OBLN Shareholders About Its Ongoing Investigations 2021/03/19 19:42:00 PR Newswire
NEW YORK, March 19, 2021 /PRNewswire/ -- Tilray, Inc. (NASDAQ: TLRY) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tilray, Inc. (NASDAQ: TLRY) in connection with the company's proposed merger with Aphria Inc….
SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations 2021/03/12 20:31:00 Benzinga
NEW YORK , March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: CONTACT: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor New York , NY 10036 (212) 682-3025 (888) 593-4771 Full story available on Benzinga.com
Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock - Stocks News Feed 2021/02/19 18:38:38 Stocks News Feed
BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.00 per share in a registered direct offering. The closing… Read More »Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock
Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock 2021/02/19 18:30:00 Yahoo Finance
BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout 2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.